IN8bio Q2 FY26 net loss narrows to $4.8 million; cash falls to $18 million

Reuters2026/08/06 20:09

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

IN8bio posted a Q2 net loss of $4.8 million, narrowing from $5.1 million a year earlier; loss per share improved to $0.25 from $1.24.
R&D expense was flat at $2.5 million; G&A expense fell 10% to $2.4 million.
Cash totaled $18 million at June 30, 2026, down from $27.09 million at Dec. 31, 2025.
ASCO 2026 update showed DeltEx DRI repeat dosing in newly diagnosed GBM with mOS above 19.5 months, mPFS of 13 months; 43% alive at 24 months.
Management said INB-619 advanced into IND-enabling studies; initial in vivo preclinical data remains targeted for H2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608061601PRIMZONEFULLFEED9804525) on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

IN8bio Q2 FY26 net loss narrows to $4.8 million; cash falls to $18 million

You may also like

Crypto prices